resTORbio, Inc. (NASDAQ:TORC)’s share price reached a new 52-week low during mid-day trading on Thursday . The company traded as low as $13.90 and last traded at $14.30, with a volume of 107712 shares. The stock had previously closed at $14.70.

TORC has been the subject of a number of research reports. Wedbush initiated coverage on resTORbio in a report on Tuesday, February 20th. They issued an “outperform” rating and a $30.00 price objective for the company. Evercore ISI initiated coverage on resTORbio in a report on Tuesday, February 20th. They issued an “outperform” rating and a $28.00 price objective for the company. Leerink Swann initiated coverage on resTORbio in a report on Tuesday, February 20th. They issued an “outperform” rating and a $36.00 price objective for the company. Finally, Bank of America initiated coverage on resTORbio in a report on Tuesday, February 20th. They issued a “buy” rating and a $23.00 price objective for the company.

How to Become a New Pot Stock Millionaire

In other news, major shareholder Puretech Health Llc acquired 233,333 shares of the business’s stock in a transaction dated Tuesday, January 30th. The stock was purchased at an average cost of $15.00 per share, for a total transaction of $3,499,995.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Orbimed Advisors Llc acquired 533,333 shares of the business’s stock in a transaction dated Tuesday, January 30th. The stock was purchased at an average price of $15.00 per share, with a total value of $7,999,995.00. The disclosure for this purchase can be found here.

WARNING: This report was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another domain, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this report can be accessed at https://www.watchlistnews.com/restorbio-torc-sets-new-1-year-low-at-13-90/1957217.html.

About resTORbio

resTORbio, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. It focuses on the mechanistic target of rapamycin (mTOR) pathway that regulates aging, and specifically on selective inhibition of the target of rapamycin complex 1 (TORC1).

Receive News & Ratings for resTORbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for resTORbio and related companies with MarketBeat.com's FREE daily email newsletter.